Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you stop taking Wegovy, appetite typically returns within days to weeks and some of the weight lost during treatment can come back over the following months. That pattern is well documented in clinical trial follow-up data, and it is the main reason prescribers treat stopping semaglutide as a planned clinical decision rather than something to do quietly. These are prescription-only medicines and any decision to stop or pause them should involve the clinician who oversees your care.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: it's a Tuesday morning, you lift your Wegovy pen from the fridge door, and you decide today is the last dose. The biology that follows is fairly predictable. Semaglutide works by activating GLP-1 receptors involved in appetite regulation and gastric emptying. Once the drug clears your system, those receptors go back to their baseline state. For most people that means hunger comes back, not dramatically overnight, but noticeably, usually within a week or two of the final injection.
This is not a sign something has gone wrong. It is simply the medicine's mechanism working in reverse. The NHS patient information for semaglutide notes that weight management medicines work alongside lifestyle changes, and that stopping the medicine removes the pharmacological support those changes were built on top of. Understanding that framing helps set realistic expectations. The question is less "will anything change?" and more "by how much, and how fast?"
Some people stop because they have reached their goal weight and feel confident managing things independently. Others stop because of side effects, cost, or a pregnancy plan. The reason shapes the plan, which is why a conversation with your prescriber before the final pen is genuinely useful rather than just procedural. If you are curious about what the effects of stopping Wegovy are likely to be, there is a detailed look at what happens to your body after stopping Wegovy, covering the timeline and what to watch for.
The STEP 1 trial extension is the clearest reference point. After 68 weeks of treatment, participants who stopped semaglutide regained, on average, around two-thirds of the weight they had lost over the following 12 months, while lifestyle support continued. Those who stayed on the medicine maintained their results. The published paper in the New England Journal of Medicine covers this follow-up period in detail.
Two-thirds is an average, not a ceiling or a floor. Some people regain very little; others regain most of what they lost. The factors that appear to matter include how embedded the dietary and activity changes became during treatment, whether there are underlying metabolic conditions, and whether stopping semaglutide was gradual in the behavioural sense (winding down portion sizes independently) even if the dose itself does not need tapering medically.
There is a specific page on weight gain after stopping Wegovy if that is the part you most want to think through. The short version: weight regain is common and biological, not a personal failure, and there are practical steps that reduce it.
Unlike some medicines, there is no medically required dose taper for stopping Wegovy. You do not need to step down from 2.4mg to 1.7mg to 1.0mg before finishing. The clinical consideration is about what happens after the final dose, not the dose itself.
Stopping semaglutide after a very short time carries different implications than stopping after a full treatment course. Someone who has been on the medicine for two years and stopped after reaching a stable weight is in a different position from someone who has only completed a few injections. The prescriber's job is to understand which situation applies and plan accordingly, whether that means agreeing a finish date, discussing coming off once the weight-loss goal is met, or flagging that stopping now might not be in your best interest given where you are in the treatment journey.
If cost is part of the decision, it is worth knowing what a full treatment package actually covers before comparing prices. Our treatment page sets out what is included at each stage. And if you are weighing up the medicine itself before committing to a course, the Wegovy overview covers licensing, how it works, and UK eligibility in one place.
The people who do best after stopping semaglutide tend to have treated the treatment period as a window to rebuild habits, not just to lose weight. GLP-1 medicines reduce appetite but do not permanently alter metabolism or fat cells. Once the appetite suppression lifts, the environment and the habits you have built are what remain.
That is not a lecture; it is a practical point. Protein intake, regular meals, resistance exercise and adequate sleep all have evidence behind them for weight maintenance, and the NHS guidance on healthy weight covers the accessible version of that evidence. A dietitian, if you can access one, can make this much more specific to your situation.
Some people who stop Wegovy decide later that they want to restart treatment. That is a clinical decision too, not something to navigate alone. Our prescribers review every patient individually, there is no automated system making these calls. If you are weighing up what to do next, a consultation is the right starting point. Start your free consultation and a GPhC-registered prescriber will review your situation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.